While further work is needed to elucidate the role(s) of IGFBP5 in the progression of NAFLD and NASH, it does appear that expression of IGFBP5 impacts NAFLD patient prognosis and regulates hepatocellular lipogenesis. The gene discussed is IGFBP5; the disease is metabolic dysfunction-associated steatohepatitis.